Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials

Table 2

Solid tumor responses comparisons of HCC patients.

Comparisons	Studies	Groups	Clinical responses (%)	Heterogeneity				RR	95% CI	P value
				Chi^2	df	P	(%)
Complete response (CR)	[22, 23, 29, 30, 32, 34–36]	Treatment	44/442 (10.0)	3.07	7	0.88	0	1.47	0.96–2.24	0.07
		Control	26/406 (6.4)
Partial response (PR)	[20, 22–25, 27, 29, 30, 32, 34–36, 38]	Treatment	210/610 (34.4)	9.96	12	0.62	0	1.30	1.10–1.53	0.002
		Control	145/551 (26.3)
Stable disease (SD)	[20, 22–25, 27, 29, 30, 32, 34–36, 38]	Treatment	260/610 (42.6)	15.89	12	0.2	24	0.95	0.84–1.08	0.47
		Control	241/551 (43.7)
Progressive disease (PD)	[20, 22–25, 27, 29, 30, 32, 34–36, 38]	Treatment	101/610 (16.6)	9.22	12	0.68	0	0.64	0.52–0.80	0.0001
		Control	146/551 (26.5)
Total response rate (tRR)	[20, 22–25, 27, 29, 30, 32, 34–36, 38]	Treatment	254/610 (41.6)	13.56	12	0.33	12	1.3	1.16–1.53	0.0001
		Control	171/551 (31.0)